Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.

Saved in:
Bibliographic Details
Title: Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
Authors: Darby RA; Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Headington, UK.; Structural Genomics Consortium and Target Discovery Institute, University of Oxford, Old Road Campus, NDM Research Building, Oxford, OX3 7FZ, UK., Unsworth A; Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Headington, UK., Knapp S; Structural Genomics Consortium and Target Discovery Institute, University of Oxford, Old Road Campus, NDM Research Building, Oxford, OX3 7FZ, UK., Kerr ID; School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK., Callaghan R; Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Headington, UK. richard.callaghan@anu.edu.au.; Division of Biomedical Science and Biochemistry, Research School of Biology, The Australian National University, Canberra, ACT, 0200, Australia. richard.callaghan@anu.edu.au.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2015 Oct; Vol. 76 (4), pp. 853-64. Date of Electronic Publication: 2015 Sep 09.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0843
DOI:10.1007/s00280-015-2858-9